

**STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED 30 JUNE 2017**

(Rs. in Lakhs)

Particulars	3 months ended 30-Jun-17	Preceding 3 months ended 31-Mar-17	Corresponding 3 months ended in the previous year 30-Jun-16	Previous year ended 31-Mar-17
	UNAUDITED	AUDITED (Refer Note 5)	UNAUDITED	AUDITED
I Revenue from operations	11,168.50	10,240.30	9,021.32	39,221.30
II Other income	465.20	720.60	396.72	2,009.40
III Total income (I+II)	11,633.70	10,960.90	9,418.04	41,230.70
IV Expenses				
(a) Cost of materials consumed	4,526.70	5,129.55	4,537.84	19,536.50
(b) Purchases of stock-in-trade	1,349.20	1,341.01	258.93	3,161.80
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	146.10	(674.94)	(21.81)	(912.30)
(d) Excise duty on sale of goods	361.70	391.01	364.67	1,381.80
(e) Employee benefits expense	1,021.70	781.14	1,139.09	4,223.20
(f) Finance costs	202.20	224.20	215.98	836.00
(g) Depreciation and amortisation expense	565.10	707.32	568.31	2,516.80
(h) Other expenses	2,907.80	2,738.72	2,546.73	10,488.10
Total expenses (IV)	11,080.50	10,638.01	9,609.74	41,231.90
V Profit / (loss) before exception items and tax (III-IV)	553.20	322.89	(191.70)	(1.20)
VI Exception items	-	-	-	-
VII Profit / (loss) before tax (V-VI)	553.20	322.89	(191.70)	(1.20)
VIII Tax expense	-	-	-	-
IX Profit / (loss) for the period (VII-VIII)	553.20	322.89	(191.70)	(1.20)
X Other comprehensive income				
Items that will not be reclassified to profit or loss				
(a) Re-measurements of defined benefits plans	1.90	(45.13)	16.37	7.00
(b) Fair value gain / (loss) from investment in equity instruments	(3,230.80)	1,204.68	1,338.83	339.10
Total other comprehensive income for the period, net of taxes	(3,228.90)	1,159.55	1,355.20	346.10
XI Total comprehensive income for the period (IX+X)	(2,675.70)	1,482.44	1,163.50	344.90
XII Earnings per equity share: (Face value of Rs. 2 each)				
(1) Basic (in Rs.)	0.23	0.13	(0.08)	(0.00)
(2) Diluted (in Rs.)	0.23	0.13	(0.08)	(0.00)
See accompanying notes to financial results				

**Notes:**

- The unaudited financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 03 August 2017. The statutory auditors have carried out limited review of the financial results for the quarter ended 30 June 2017.
- The Company has only one reportable segment viz. Pharmaceuticals. Accordingly, no separate disclosure of segment information has been made.
- The Board of Directors of the Company at their meeting held on 20 March 2017 have approved a scheme for de-merger of Human API business, subject to the approval from the shareholders, applicable laws, consents, permissions and sanctions as may be necessary. The Company's Human API business is proposed to be de-merged into a new listed entity. The above decision is in line with the Company's focus on value creation in Animal Healthcare.
- The previous period figures have been regrouped wherever necessary to correspond with the current period disclosure.
- The above results includes the results for the quarter ended 31 March 2017, being the balancing figure between audited figures in respect of the full financial year and the recast published year to date figures up to the third quarter of the previous financial year.

For Sequent Scientific Limited

  
Manish Gupta  
Managing Director

Place : Thane  
Date: 03 August 2017



**Sequent**  
Proven Ability in Life Sciences  
**SEQUENT SCIENTIFIC LIMITED**

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED 30 JUNE 2017**

(Rs. in Lakhs)

Particulars	3 months ended 30-Jun-2017	Preceding 3 months ended 31-Mar-2017	Corresponding 3 months ended in the previous year 30-Jun-2016	Previous year ended 31-Mar- 2017
	UNAUDITED	AUDITED (Refer Note 6)	UNAUDITED	AUDITED
I Revenue from operations	26,054.10	25,441.05	16,872.24	91,508.10
II Other income	373.40	8.03	219.37	1,107.50
III Total Income (I+II)	26,427.50	25,449.08	17,091.61	92,615.60
IV Expenses				
(a).Cost of materials consumed	11,733.40	12,065.57	5,811.61	39,014.10
(b).Purchase of stock-in-trade	2,075.00	2,319.60	2,099.60	7,244.60
(c).Changes in inventories of finished goods, work-in-progress and stock-in-trade	(679.20)	(2,288.31)	(146.44)	(1,886.30)
(d).Excise duty on sale of goods	399.80	446.20	391.90	1,543.70
(e).Employee benefits expense	3,339.70	3,338.64	2,830.77	13,055.40
(f). Finance costs	950.20	940.87	810.30	3,627.70
(g).Depreciation and amortisation expense	1,505.60	1,565.74	1,326.89	6,229.50
(h).Other expense	6,032.50	5,875.67	4,677.79	23,723.10
Total expenses	25,357.00	24,263.98	17,802.42	92,551.80
V Profit/(loss) from continuing operations before tax and exceptional item (III-IV)	1,070.50	1,185.10	(710.81)	63.80
VI Exceptional items	-	-	-	-
VII Profit/(loss) from continuing operations before tax (V-VI)	1,070.50	1,185.10	(710.81)	63.80
VIII Tax expense				
(a).Current tax	223.30	194.00	83.30	706.50
(b).Deferred tax	(30.70)	(308.46)	(33.94)	(376.60)
(c).Prior period taxes	-	(371.20)	-	(371.20)
Total tax expenses	192.60	(485.66)	49.36	(41.30)
IX Profit/(loss) from continuing operations after tax (VII-VIII)	877.90	1,670.76	(760.17)	105.10
Profit/(loss) from discontinued operation	(653.20)	(612.25)	(434.89)	(1,743.80)
Tax expense of discontinued operation	-	8.56	(8.56)	-
X Profit/(loss) from discontinued operations after tax	(653.20)	(620.81)	(426.33)	(1,743.80)
XI Profit/(loss) for the period (IX+X)	224.70	1,049.95	(1,186.50)	(1,638.70)
XII Other comprehensive income				
Items that will not be reclassified to profit or loss				
(a).Re-measurement gains/(losses) on defined benefits plans	(3.60)	(56.70)	14.20	(14.40)
(b).Fair value gain / (loss) from investment in equity instruments	(3,230.80)	1,204.70	1,337.80	339.10
Items that may be reclassified to profit or loss				
(a).Exchange differences on translation of foreign operations	(66.10)	(276.85)	(280.71)	(348.63)
(b).Exchange differences on net investment in foreign operations	98.80	(645.12)	-	(407.87)
Total other comprehensive income	(3,201.70)	226.03	1,071.29	(431.80)
XIII Total comprehensive income for the period (XI+XII)	(2,977.00)	1,275.98	(115.21)	(2,070.50)
Profit for the period attributable to:				
- Owners of the Company	223.70	682.25	(1,024.90)	(1,382.40)
- Non-controlling interests	1.00	367.70	(161.60)	(256.30)
Other comprehensive income for the period attributable to:				
- Owners of the Company	(3,269.00)	352.05	1,071.29	(298.20)
- Non-controlling interests	67.30	(126.02)	-	(133.60)
Total comprehensive income for the period attributable to:				
- Owners of the Company	(3,045.30)	1,034.30	46.39	(1,680.60)
- Non-controlling interests	68.30	241.68	(161.60)	(389.90)
Earnings per equity share (for continuing operations)				
(1) Basic (in Rs.)	0.21	0.38	(0.34)	(0.26)
(2) Diluted (in Rs.)	0.21	0.38	(0.34)	(0.26)
Earnings per equity share (for discontinued operations)				
(1) Basic (in Rs.)	(0.12)	(0.10)	(0.09)	(0.32)
(2) Diluted (in Rs.)	(0.12)	(0.10)	(0.09)	(0.32)
Earnings per equity share (for continuing and discontinued operations)				
(1) Basic (in Rs.)	0.09	0.28	(0.43)	(0.58)
(2) Diluted (in Rs.)	0.09	0.28	(0.43)	(0.58)
See accompanying notes to the financial results				
Notes:	<p>1. The unaudited financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 03 August 2017. The statutory auditors have carried out limited review of the financial results for the quarter ended 30 June 2017.</p> <p>2. With effect from 01 April, 2017 the Chief Operating Decision Maker (CODM) reviews the operations as one segment "Pharmaceuticals". Accordingly the segment information for earlier periods have been restated in line with provisions of Ind AS 108 "Operating Segments".</p>			



**Sequent**  
Proven Ability in Life Sciences  
**SEQUENT SCIENTIFIC LIMITED**

**3. Information on Standalone Results:**

(Rs in Lakhs)

Particulars	3 months ended 30-Jun-2017	Preceding 3 months ended 31-Mar-2017	Corresponding 3 months ended in the previous year 30-Jun-2016	Previous year ended 31-Mar- 2017
	UNAUDITED	AUDITED (Refer Note 6)	UNAUDITED	AUDITED
Revenue from operations	11,168.50	10,240.30	9,021.32	39,221.30
Profit before tax	553.20	322.89	(191.70)	(1.20)
Profit after tax	553.20	322.89	(191.70)	(1.20)
Total comprehensive income	(2,675.70)	1,482.44	1,163.50	344.90

4. Pursuant to the approval of Board of Directors of the Company and shareholders received vide postal ballot dated 24 March 2017 for the divestment of woman healthcare business, the company has entered into a definitive agreement for sale of subsidiary (Naari Pharma Private Limited) with Tenshi Life Science Private Limited and accordingly as on 30 June 2017 the assets and liabilities of the subsidiary has been classified as held for sale, pending completion of certain conditions precedent and other customary closing conditions. The results relating to the discontinued woman healthcare business are as follows :

(Rs. in Lakhs)

Particulars	3 months ended 30-Jun-2017	Preceding 3 months ended 31-Mar-2017	Corresponding 3 months ended in the previous year 30-Jun-2016	Previous year ended 31-Mar- 2017
	Total Income	1,755.90	1,797.81	1,213.89
Total Expenses	2,409.10	2,410.06	1,648.78	8,616.26
Profit / (loss) before exceptional item and tax	(653.20)	(612.25)	(434.89)	(1,743.80)
Exceptional items	-	-	-	-
Profit/ (Loss) before tax	(653.20)	(612.25)	(434.89)	(1,743.80)
Tax expense	-	8.56	(6.56)	-
Profit/ (Loss) for the period	(653.20)	(620.81)	(426.33)	(1,743.80)

5. The Board of Directors of the Company at their meeting held on 20 March 2017 have approved a scheme for de-merger of Human API business, subject to the approval from the shareholders, applicable laws, consents, permissions and sanctions as may be necessary. The Company's Human API business is proposed to be de-merged into a new listed entity. The above decision is in line with the Company's focus on value creation in Animal Healthcare.

6. The above results includes the results for the quarter ended 31 March 2017, being the balancing figure between audited figures in respect of the full financial year and the recast published year to date figures up to the third quarter of the previous financial year.

7. The previous period figures have been regrouped wherever necessary to correspond with the current period disclosure.

For Sequent Scientific Limited

  
Manish Gupta  
Managing Director

Place : Thane  
Date : 03 August 2017



# Deloitte Haskins & Sells

Chartered Accountants  
Deloitte Centre  
Anchorage II  
100/2 Richmond Road  
Bengaluru - 560 025  
India

Tel: +91 (080) 6627 6000  
Fax: +91 (080) 6627 6013

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF SEQUENT SCIENTIFIC LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **SEQUENT SCIENTIFIC LIMITED** ("the Company"), for the Quarter ended June 30, 2017 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

WJ

# Deloitte Haskins & Sells

3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**  
Chartered Accountants  
(Firm's Registration No. 008072S)



**Sathya P. Koushik**  
Partner  
(Membership No. 206920)

Thane, August 3, 2017  
SPK/JKS/2017

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF SEQUENT SCIENTIFIC LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **SEQUENT SCIENTIFIC LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2017 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Parent's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. The Statement includes the results of the following entities:
  - i) Alivira Animal Health Australia Pty Ltd;
  - ii) Alivira Animal Health Limited, Ireland;
  - iii) Alivira Animal Health Limited, India;
  - iv) Alivira Saude Animal Brasil Participacoes Ltda;
  - v) Alivira UA Limited;
  - vi) Comercial Vila Veterinaria de Lleida S.L;

# Deloitte Haskins & Sells

- vii) Elysian Life Sciences Private Limited;
  - viii) Fendigo BV;
  - ix) Fendigo SA;
  - x) Interchange Veterinária Indústria E Comércio Ltda;
  - xi) Laboratorios Karizoo, S.A;
  - xii) Laboratorios Karizoo, S.A. De C.V. (Mexico);
  - xiii) N-Vet AB;
  - xiv) Naari Pharma Private Limited;
  - xv) Phytotherapeutic Solutions S.L;
  - xvi) Provet Veteriner Urunleri Sanayi ve Ticaret A.S;
  - xvii) SeQuent Antibiotics Private Limited;
  - xviii) SeQuent Global Holdings Limited;
  - xix) SeQuent Penems Private Limited;
  - xx) SeQuent Pharmaceuticals Private Limited;
  - xxi) SeQuent Research Limited;
  - xxii) Sequent Scientific Pte. Ltd;
  - xxiii) Topkim-Topkapi Ilac Premiks San. ve Tic. A.S;
  - xxiv) Vila Viña Participacions S.L;
4. Based on our review conducted as stated above and based on the consideration of the review reports of other auditors referred to in paragraph 5 below, and except for the possible effects of the matters described in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. In respect of continuing operations, we did not review the interim financial results of eight subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs.9,960.89 lakhs for the quarter ended June 30, 2017, and total profit after tax of Rs.685.59 lakhs and total comprehensive income of Rs.685.59 lakhs for the quarter ended June 30, 2017, as considered in the consolidated unaudited financial results.

# Deloitte Haskins & Sells


In respect of discontinuing operations, we did not review the financial results of one subsidiary included in the consolidated financial results, whose financial statements reflect total revenues of Rs.1,755.94 lakhs, total net loss after tax of Rs.748.66 lakhs and total comprehensive loss of Rs.755.82 lakhs for the quarter ended on that date, as considered in the consolidated unaudited financial results.

These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our report on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors.

Our report on the Statement is not modified in respect of these matters.

6. In respect of continuing operations, the consolidated unaudited financial results includes the interim financial results of fourteen subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total revenue of Rs.3,028.30 lakhs for the quarter ended June 30, 2017, and total profit after tax of Rs.264.43 lakhs and total comprehensive income of Rs.266.71 lakhs for the quarter ended June 30, 2017, as considered in the consolidated unaudited financial results.

For **DELOITTE HASKINS & SELLS**  
Chartered Accountants  
(Firm's Registration No. 008072S)



**Sathya P. Koushik**  
Partner  
(Membership No. 206920)

Thane, August 3, 2017  
SPK/JKS/2017